To include your compound in the COVID-19 Resource Center, submit it here.

MyoKardia's mavacamten meets in Phase II for HCM

MyoKardia Inc. (NASDAQ:MYOK) reported top-line data from 10 evaluable patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM) in the first cohort of the Phase II PIONEER-HCM trial showing that once-daily 10 or 15 mg

Read the full 337 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE